Banner

Multiple Sclerosis Drugs Global Market Report 2022 – By Drug Class (Immunomodulators, Immunosuppressants, Interferons), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Stores), By Route Of Administration (Oral Drugs, Parenteral Drugs) – Market Size, Trends, And Global Forecast 2022-2026

Starting Price : $5000.00 | Pages : 150 | Published : October 2022 | SKU CODE : 7608 | Delivery Time: 2-3 business days | Format :


The multiple sclerosis drugs market consists of the sale of multiple sclerosis drugs and related services. Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the protective fat layer called myelin, around the nerve fibers and causes problems with muscle control, vision, and other body functions. It is a disease that affects the brain, spinal cord, and optic nerves resulting in loss of balance, coordination, and compromised vision. The disease can result in long-term disability.

The main drug class of multiple sclerosis drugs is immunomodulators, immunosuppressants, interferons, and others. Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The various route of administration includes oral drugs and parenteral drugs that are distributed through hospital pharmacy, retail pharmacy, and online stores.

The multiple sclerosis drugs market research report is one of a series of new reports from The Business Research Company that provides multiple sclerosis drugs market statistics, including multiple sclerosis drugs industry global market size, regional shares, competitors with a multiple sclerosis drugs market share, detailed multiple sclerosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the multiple sclerosis drugs industry. This multiple sclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The global multiple sclerosis drugs market is expected to grow from $24.75 billion in 2021 to $26.29 billion in 2022 at a compound annual growth rate (CAGR) of 6.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The multiple sclerosis drugs market is expected to reach $33.46 billion in 2026 at a CAGR of 6.2%.

The growth of the multiple sclerosis drugs market is aided by the support from the government as well as non-government organizations. The government and non-government organizations fund several schemes and programs to offer their support to enhance the quality of life of people affected with multiple sclerosis (MS). For instance, in 2019, the government of Alberta in partnership with the Department of Economic Development, Trade, and Tourism in Canada invested $ 1 million towards the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) to support the research and innovations to enhance understanding and treatment for MS disease. CanProCo is an initiative to consolidate the efforts of nearly 50 MS researchers from various disciplines across Canada. The initiative was further funded by the Canada Brain Research, Biogen Canada, and the MS Society of Canada, as well as Hoffmann-La Roche Limited (Roche Canada) to raise a total of $10 million. Appropriate financial support from the government and non-government organizations boosts the growth of the multiple sclerosis drugs market.

The high cost of drugs to treat multiple sclerosis (MS) restricts the growth of the multiple sclerosis drugs market. MS is a cureless disease with high chances of a disability and requires lifelong treatment. Despite the heavy competition among the drug companies, the cost of MS drugs is high, increasing the overall cost of treatment. The companies operating in the multiple sclerosis drugs market often have to work towards reducing the cost of these drugs to justify their cost-effectiveness to their consumers. As reported by Institute for Clinical and Economic Review (ICER), MS drugs cost roughly between $63,000 and $104,000 annually. For instance, in 2019, after receiving criticism from the National Multiple Sclerosis Society on the high price of Vumerity, a drug to treat relapse MS, Biogen and Alkermes had to reduce the prices of the drug to $88,000 per year to make it affordable to the patients. The high cost of drugs, which are required lifelong negatively affects the growth of the multiple sclerosis drugs market.

The companies are rapidly intensifying their efforts to focus on new product launches to cater to the rising demands for MS drugs. Multiple sclerosis requires lifelong treatment, which increases the overall cost of treating a patient. To provide better and more effective treatment companies in the multiple sclerosis market are developing drugs specific to the treatment of multiple sclerosis. Following the trend, in 2019, FDA approved Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribine) for the treatment of relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS). Both the drugs were launched as easy-to-consume oral drugs.

In 2019, Bristol-Myers Squibb, a USA-based pharmaceutical company, acquired Celgene for $74billion. Through the acquisition, Bristol-Myers Squibb aims to increase its product portfolio by utilizing the existing products of Celgene along with its technical and pipeline support. Ozanimod is one of Celgene’s pipelined drugs for the treatment of relapsing multiple sclerosis. The drug is currently in phase III clinical trials to be approved by FDA. Celgene is a USA-based producer and marketer of medicines for cancer and inflammatory disorders such as multiple sclerosis.

Major players in the multiple sclerosis drugs market are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer Inc., Merck & Co. Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, Acorda Therapeutics Inc., Actelion Pharmaceutical, EMD Serono, AbbVie Inc., Betaseron, CinnoVex, Extavia, Rebif and Tysabr.

North America was the largest region in the multiple sclerosis drug market in 2021. Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the multiple sclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the multiple sclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global multiple sclerosis drugs market is segmented -

1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Others

2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores

3) By Route Of Administration: Oral Drugs, Parenteral Drugs

    Table Of Contents

    1. Executive Summary

    2. Multiple Sclerosis Drugs Market Characteristics

    3. Multiple Sclerosis Drugs Market Trends And Strategies

    4. Multiple Sclerosis Drugs Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Multiple Sclerosis Drugs Market

    4.2 Ukraine-Russia War Impact On Multiple Sclerosis Drugs Market

    4.3 Impact Of High Inflation On Multiple Sclerosis Drugs Market

    5. Multiple Sclerosis Drugs Market Size And Growth

    5.1. Global Multiple Sclerosis Drugs Historic Market, 2016-2021, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Multiple Sclerosis Drugs Forecast Market, 2021-2026F, 2031F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Multiple Sclerosis Drugs Market Segmentation

    6.1. Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Immunomodulators

    Immunosuppressants

    Interferons

    Others

    6.2. Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Stores

    6.3. Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Oral Drugs

    Parenteral Drugs

    7. Multiple Sclerosis Drugs Market Regional And Country Analysis

    7.1. Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    7.2. Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8. Asia-Pacific Multiple Sclerosis Drugs Market

    8.1. Asia-Pacific Multiple Sclerosis Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8.3. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    9. China Multiple Sclerosis Drugs Market

    9.1. China Multiple Sclerosis Drugs Market Overview

    9.2. China Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    9.3. China Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    10. India Multiple Sclerosis Drugs Market

    10.1. India Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    10.2. India Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11. Japan Multiple Sclerosis Drugs Market

    11.1. Japan Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11.2. Japan Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12. Australia Multiple Sclerosis Drugs Market

    12.1. Australia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12.2. Australia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13. Indonesia Multiple Sclerosis Drugs Market

    13.1. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13.2. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14. South Korea Multiple Sclerosis Drugs Market

    14.1. South Korea Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14.2. South Korea Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15. Western Europe Multiple Sclerosis Drugs Market

    15.1. Western Europe Multiple Sclerosis Drugs Market Overview

    15.2. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15.3. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16. UK Multiple Sclerosis Drugs Market

    16.1. UK Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16.2. UK Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17. Germany Multiple Sclerosis Drugs Market

    17.1. Germany Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17.2. Germany Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18. France Multiple Sclerosis Drugs Market

    18.4. France Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18.5. France Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19. Eastern Europe Multiple Sclerosis Drugs Market

    19.1. Eastern Europe Multiple Sclerosis Drugs Market Overview

    19.2. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19.3. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20. Russia Multiple Sclerosis Drugs Market

    20.1. Russia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20.2. Russia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21. North America Multiple Sclerosis Drugs Market

    21.1. North America Multiple Sclerosis Drugs Market Overview

    21.2. North America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21.3. North America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22. USA Multiple Sclerosis Drugs Market

    22.1. USA Multiple Sclerosis Drugs Market Overview

    22.2. USA Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22.3. USA Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23. South America Multiple Sclerosis Drugs Market

    23.1. South America Multiple Sclerosis Drugs Market Overview

    23.2. South America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23.3. South America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24. Brazil Multiple Sclerosis Drugs Market

    24.1. Brazil Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24.2. Brazil Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25. Middle East Multiple Sclerosis Drugs Market

    25.1. Middle East Multiple Sclerosis Drugs Market Overview

    25.2. Middle East Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25.3. Middle East Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26. Africa Multiple Sclerosis Drugs Market

    26.1. Africa Multiple Sclerosis Drugs Market Overview

    26.2. Africa Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26.3. Africa Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    27. Multiple Sclerosis Drugs Market Competitive Landscape And Company Profiles

    27.1. Multiple Sclerosis Drugs Market Competitive Landscape

    27.2. Multiple Sclerosis Drugs Market Company Profiles

    27.2.1. Biogen

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Novartis

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Roche

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Bayer HealthCare

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Pfizer, Inc.

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Multiple Sclerosis Drugs Pipeline Analysis

    29. Key Mergers And Acquisitions In The Multiple Sclerosis Drugs Market

    30. Multiple Sclerosis Drugs Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Table 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Table 3: Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 4: Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 5: Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 6: Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7: Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10: China, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11: China, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 12: India, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 13: India, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 14: Japan, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 15: Japan, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 16: Australia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 17: Australia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 18: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 19: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 20: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 21: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 22: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 23: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 24: UK, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 25: UK, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 26: Germany, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 27: Germany, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 28: France, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 29: France, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 30: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 31: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 32: Russia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 33: Russia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 34: North America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 35: North America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 36: USA, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 37: USA, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 38: South America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 39: South America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 40: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 41: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 42: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 43: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 44: Africa, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 45: Africa, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 46: Biogen Financial Performance
  • Table 47: Novartis Financial Performance
  • Table 48: Roche Financial Performance
  • Table 49: Bayer HealthCare Financial Performance
  • Table 50: Pfizer, Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Figure 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Figure 3: Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 4: Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 5: Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 6: Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7: Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10: China, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11: China, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 12: India, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 13: India, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 14: Japan, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 15: Japan, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 16: Australia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 17: Australia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 18: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 19: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 20: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 21: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 22: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 23: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 24: UK, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 25: UK, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 26: Germany, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 27: Germany, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 28: France, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 29: France, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 30: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 31: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 32: Russia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 33: Russia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 34: North America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 35: North America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 36: USA, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 37: USA, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 38: South America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 39: South America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 40: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 41: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 42: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 43: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 44: Africa, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 45: Africa, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 46: Biogen Financial Performance
  • Figure 47: Novartis Financial Performance
  • Figure 48: Roche Financial Performance
  • Figure 49: Bayer HealthCare Financial Performance
  • Figure 50: Pfizer, Inc. Financial Performance
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
The Business Research Company offers the anti-parkinson drugs market research report 2022 with industry size, share, segments and market growth
The Business Research Company offers the pancreatic cancer drugs market research report 2022 with industry size, share, segments and market growth
Best Prospects in the Global Hormonal Contraceptives Market and Strategies for Growth – Includes Hormonal Contraceptives Market Share
Take Up Global Biosimilars Market Opportunities With Clear Industry Data – Includes Biosimilars Market Size
Take Up Global Nucleic Acid Based Gene Therapy Market Opportunities with Clear Industry Data – Includes Nucleic Acid Based Gene Therapy Market Size
Global Enzyme Inhibitor Market Overview And Prospects – Includes Enzyme Inhibitor Market Share
CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Over-The-Counter Drugs, Prescription-Based Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Interferons Global Market Report 2022 – By Type (Inteferon Alpha, Inteferon Beta, Inteferon Gamma), By Application (Hepatitis B, Hepatitis C, Melanoma, Leukemia, Multiple Sclerosis, Renal Cell Carcinoma), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Immunosuppressants Global Market Report 2022 – By Drug Class (Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents), By Indication (Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Bi-Specific MAbS Global Market Report 2022 – By Type (Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597), By Product Type (In Vivo, In Vitro), By Indication (Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases), By End Use (Hospitals, Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Biologics Global Market Report 2022 – By Type (Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Autoinjectors Global Market Report 2022 – By Type (Disposable Autoinjectors, Reusable Autoinjectors), By Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis), By Route Of Administration (Subcutaneous, Intramuscular), By Distribution Channel (Online Retailer, Pharmacy), By End User (Home Care Settings, Hospitals And Clinics) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Biosimilar Lymphocyte Modulator Global Market Report 2022 – By Drug (Campath-1H, Natalizumab Biosimilar, Efalizumab - A1089-Anti-CD11a Bisoimilar, Anti-CD38 Daratumumab Biosimilar, Anti-CS1 Elotuzumab Bisoimilar), By Disease (Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Psoriasis) – Market Size, Trends, And Global Forecast 2022-2026
View Report